Huang Han, Gan Chenxiao, Cai Yan, Wu Lingkang
The Second School of Clinical Medicine, Zhejiang Chinese Medical University, China.
School of Basic Medical Sciences, Zhejiang Chinese Medical University, China.
Cent Eur J Immunol. 2024;49(1):70-76. doi: 10.5114/ceji.2024.136376. Epub 2024 Mar 25.
Inflammatory bowel disease (IBD) is a group of diseases characterized by refractory and chronic inflammation of the bowel, which can be treated with biologics in clinical practice. Anti-tumor necrosis factor α (TNF-α) agents, which are among the most widely used biologics, alleviate the inflammatory activity in a variety of ways. Helicobacter pylori is a Gram-negative bacterium that colonizes the gastric mucosa, which could cause chronic inflammation and even induce gastric cancer. However, it has been suggested that H. pylori has a potential protective role in IBD patients. Yet there has been limited research on the mechanisms of the effect of H. pylori infection in IBD patients, and whether there is an interaction between H. pylori and anti-TNF-α agents. This review aims to summarize the possible mechanisms of H. pylori and anti-TNF-α agents in the development and treatment of IBD, and to explore the possible interaction between H. pylori infection and anti-TNF-α agents.
炎症性肠病（IBD）是一组以肠道难治性慢性炎症为特征的疾病，在临床实践中可用生物制剂进行治疗。抗肿瘤坏死因子α（TNF-α）药物是使用最广泛的生物制剂之一，可通过多种方式减轻炎症活动。幽门螺杆菌是一种定植于胃黏膜的革兰氏阴性菌，可引起慢性炎症甚至诱发胃癌。然而，有研究表明幽门螺杆菌在IBD患者中具有潜在的保护作用。然而，关于幽门螺杆菌感染对IBD患者影响的机制以及幽门螺杆菌与抗TNF-α药物之间是否存在相互作用的研究有限。本综述旨在总结幽门螺杆菌和抗TNF-α药物在IBD发生发展及治疗中的可能机制，并探讨幽门螺杆菌感染与抗TNF-α药物之间可能存在的相互作用。
